3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
8
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
selpercatinib
2
pembrolizumab
2
abemaciclib
2
Pemetrexed
2
Nivolumab
2
Irinotecan
2
Fulvestrant
2
Abiraterone Acetate
2
ribociclib
1
repotrectinib
1
relatlimab
1
pralsetinib
1
pamiparib
1
palbociclib
1
osimertinib
1
onapristone
1
olaparib
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
exemestane
1
enzalutamide
1
elacestrant
1
cobimetinib
1
abiraterone
1
Trastuzumab
1
Taxes
1
Tamoxifen
1
STX-478
1
Radiation
1
RAD1901
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasms by Site
×
elacestrant
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled